• Akero Therapeutics Inc AKRO.OQ reported a quarterly adjusted loss of 90 cents​​ per share for the quarter ended March 31, identical to the same quarter last year. The mean expectation of seven analysts for the quarter was for a loss of 89 cents per share. Wall Street expected results to range from $-1.14 to -69 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Akero Therapeutics Inc's reported EPS for the quarter was a loss of 90 cents​.

• The company reported a quarterly loss of $70.73 million.

• Akero Therapeutics Inc shares had fallen by 5.5% this quarter and gained 81.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Akero Therapeutics Inc is $75.00, about 32.7% above its last closing price of $50.45

This summary was machine generated from LSEG data August 8 at 01:56 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)